Actinium Pharmaceuticals Investors Can Lead Lawsuit with Losses Over $100K

Important Opportunity for Actinium Pharmaceuticals Investors

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) investors who have suffered significant losses exceeding $100,000 have a crucial opportunity to become involved in a securities fraud lawsuit initiated by the Rosen Law Firm. The firm emphasizes the urgency of this matter, reminding affected investors of the lead plaintiff deadline on May 27, 2025.

Overview of the Case

If you purchased Actinium securities between October 31, 2022, and August 2, 2024, you may qualify for compensation without incurring any upfront costs. The lawsuit arises from allegations of misleading statements made by company executives that ultimately led to investor damages when the true facts surrounding the company were revealed.

For those interested in joining the class action, the process is straightforward: visit the Rosen Law Firm's website or reach out directly by calling Phillip Kim, Esq. at 866-767-3653. Interested parties are urged to act promptly, as time is of the essence in filing motions to serve as lead plaintiff, a role that involves representing the interests of fellow investors in the litigation.

Why Choose Rosen Law Firm?

Rosen Law Firm has established a reputation for effectively advocating for investor rights. With a robust history of securing settlements in securities class actions, the firm emphasizes the importance of selecting experienced counsel with a proven track record in the field. Over the years, Rosen Law Firm has achieved landmark settlements, including the largest-ever securities class action settlement against a Chinese company. Notably, it was ranked first by ISS Securities Class Action Services in 2017, and it has consistently ranked among the top firms for securities settlements since 2013.

The attorneys at Rosen Law have received accolades from prominent legal recognition bodies such as Lawdragon and Super Lawyers, underscoring their expertise and commitment to serving investors effectively. Their history of securing substantial settlements—over $438 million in just 2019—demonstrates their capability to represent investor interests vigorously.

Allegations Against Actinium Pharmaceuticals

The lawsuit pertains to claims that during the stated class period, the executives of Actinium Pharmaceuticals made several false and misleading statements. Key allegations include:
1. Lack of FDA Compliance: The company allegedly failed to disclose that its clinical trial data was unlikely to meet FDA approval standards for their Iomab-B Biologics License Application (BLA).
2. Misleading Survival Trends: Additional analyses provided to the FDA concerning overall survival rates were purportedly misrepresented, lacking sufficient basis to support positive investor sentiment.
3. Consequences of Misinformation: Prominent statements about the company’s potential and future prospects may have been materially misleading, as they did not accurately reflect the unfolding realities impacting the trial's outcomes.

When these facts became public, investors faced significant losses, prompting the class action lawsuit against the company.

Next Steps for Investors

Investors who wish to participate in the class action must complete the necessary paperwork and act before the imposed deadline. Importantly, until a class is officially certified, investors are not represented unless they choose their counsel. Therefore, being proactive in navigating this situation is critical. Investors can opt to remain passive or take an active role in representing their interests.

Investors are encouraged to follow updates related to the case via social media channels maintained by the Rosen Law Firm, which include their LinkedIn and Twitter profiles.

For further inquiries, interested parties can always contact the Rosen Law Firm directly, as they prepare to advocate for investors vehemently. This is an essential moment for Actinium Pharmaceuticals investors to ensure their voices and rights are represented adequately in the face of securities fraud allegations.

Conclusion

This opportunity underscores the importance of investor awareness and engagement, especially in matters tied to potential fraudulent practices. The Rosen Law Firm stands ready to assist those affected and navigate the complexities of securities litigation. Act now to protect your rights and join the collective effort to seek redress.